Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
Healthcare
$1.61 -0.87%
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
52W Low $2.01High $48.91
Volume 0.02M
Average 0.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$3.94M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$4.47M
FY 2025 · Annual
-37.9% YoYCash Flow Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 3.24M | 2.4M | 0 |
| Change in Working Capital | 369K | (621K) | 316K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | (52K) | (401K) | 398K |
| Other Working Capital | 421K | (220K) | (82K) |
| Other Non-Cash Items | 0 | 26M | 4.73M |
| Operating Cash Flow | (173K) | (2.57M) | (3.94M) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 |
| Debt Repayment | 128K | (128K) | 0 |
| Common Stock Issued | 0 | 7.32M | 4.47M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 128K | 7.19M | 4.47M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (45K) | 4.62M | 522K |
| Free Cash Flow | (173K) | (2.57M) | (3.94M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$9.0M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$316.0K
+ Other Non-Cash$4.7M
= Operating Cash Flow-$3.9M
- Capex$0
= Free Cash Flow-$3.9M
Analysis
FY2025 free cash flow is -$3.9M. FCF conversion is 43.9% of net income. Operating cash flow was -$3.9M, with capex of $0. The largest bridge item is Other Non-Cash at $4.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Sep 14, 2026 | |
| 8-K | Current report | Sep 1, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| ARS | ARS filing | Jul 28, 2026 |
Does PLYX generate free cash flow?
Polaryx Therapeutics, Inc. Common Stock (PLYX) generated -$3.94M of free cash flow in fiscal 2025.
How much operating cash flow does PLYX produce?
Operating cash flow was -$3.94M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.